Riluzole as a neuroprotective drug for spinal cord injury: From bench to bedside

Molecules

Volumn 20, Issue 5, 2015, Pages 7775-7789

  Nagoshi, Narihito ^a,b   Nakashima, Hiroaki ^a,c   Fehlings, Michael G ^a,d  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clinical trial; Neuroprotection; Riluzole; Spinal cord injury

Indexed keywords

NEUROPROTECTIVE AGENT; RILUZOLE; SODIUM CHANNEL BLOCKING AGENT;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HUMAN; RAT; SPINAL CORD INJURIES; SYNAPTIC TRANSMISSION;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROPROTECTIVE AGENTS; RATS; RILUZOLE; SODIUM CHANNEL BLOCKERS; SPINAL CORD INJURIES; SYNAPTIC TRANSMISSION;

EID: 84929208524     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20057775     Document Type: Review

References (49)

1. Fehlings, M.G.; Vaccaro, A.; Wilson, J.R.; Singh, A.; Cadotte, D.W.; Harrop, J.S.; Aarabi, B.; Shaffrey, C.; Dvorak, M.; Fisher, C.; et al. Early versus delayed decompression for traumatic cervical spinal cord injury: Results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS). PLoS ONE 2012, 7, e32037.
2. Wilson, J.R.; Singh, A.; Craven, C.; Verrier, M.C.; Drew, B.; Ahn, H.; Ford, M.; Fehlings, M.G. Early versus late surgery for traumatic spinal cord injury: The results of a prospective Canadian cohort study. Spinal Cord 2012, 50, 840-843.
3. Labruyere, R.; Agarwala, A.; Curt, A. Rehabilitation in spine and spinal cord trauma. Spine 2010, 35 (Suppl. 21), S259-S262.
4. Bensimon, G.; Lacomblez, L.; Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994, 330, 585-591.
5. Lacomblez, L.; Bensimon, G.; Leigh, P.N.; Guillet, P.; Meininger, V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996, 347, 1425-1431.
6. Miller, R.G.; Jackson, C.E.; Kasarskis, E.J.; England, J.D.; Forshew, D.; Johnston, W.; Kalra, S.; Katz, J.S.; Mitsumoto, H.; Rosenfeld, J.; et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009, 73, 1218-1226.
7. Schwartz, G.; Fehlings, M.G. Secondary injury mechanisms of spinal cord trauma: A novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog. Brain Res. 2002, 137, 177-190.
8. Rosenberg, L.J.; Teng, Y.D.; Wrathall, J.R. Effects of the sodium channel blocker tetrodotoxin on acute white matter pathology after experimental contusive spinal cord injury. J. Neurosci. 1999, 19, 6122-6133.
9. Kretschmer, B.D.; Kratzer, U.; Schmidt, W.J. Riluzole, a glutamate release inhibitor, and motor behavior. Naunyn Schmiedebergs Arch. Pharmacol. 1998, 358, 181-190.
10. Fumagalli, E.; Funicello, M.; Rauen, T.; Gobbi, M.; Mennini, T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur. J. Pharmacol. 2008, 578, 171-176.
11. Wang, S.J.; Wang, K.Y.; Wang, W.C. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 2004, 125, 191-201.
12. Le Liboux, A.; Cachia, J.P.; Kirkesseli, S.; Gautier, J.Y.; Guimart, C.; Montay, G.; Peeters, P.A.; Groen, E.; Jonkman, J.H.; Wemer, J. A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers. J. Clin. Pharmacol. 1999, 39, 480-486.
13. Le Liboux, A.; Lefebvre, P.; Le Roux, Y.; Truffinet, P.; Aubeneau, M.; Kirkesseli, S.; Montay, G. Single- and multiple-dose pharmacokinetics of riluzole in white subjects. J. Clin. Pharmacol. 1997, 37, 820-827.
14. Bruno, R.; Vivier, N.; Montay, G.; Le Liboux, A.; Powe, L.K.; Delumeau, J.C.; Rhodes, G.R. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clin. Pharmacol. Ther. 1997, 62, 518-526.
15. Groeneveld, G.J.; van Kan, H.J.; Kalmijn, S.; Veldink, J.H.; Guchelaar, H.J.; Wokke, J.H.; van den Berg, L.H. Riluzole serum concentrations in patients with ALS: Associations with side effects and symptoms. Neurology 2003, 61, 1141-1143.
16. Bryson, H.M.; Fulton, B.; Benfield, P. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs 1996, 52, 549-563.
17. Tator, C.H.; Fehlings, M.G. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J. Neurosurg. 1991, 75, 15-26.
18. Fehlings, M.G.; Wilson, J.R.; Frankowski, R.F.; Toups, E.G.; Aarabi, B.; Harrop, J.S.; Shaffrey, C.I.; Harkema, S.J.; Guest, J.D.; Tator, C.H.; et al. Riluzole for the treatment of acute traumatic spinal cord injury: Rationale for and design of the NACTN Phase I clinical trial. J. Neurosurg. Spine 2012, 17 (Suppl. 1), 151-156.
19. 2+ exchanger. J. Neurosci. 1996, 16, 545-552.
20. 2+ influx during anoxia in mammalian central nervous system white matter. Ann. Neurol. 1991, 30, 375-380.
21. Haigney, M.C.; Lakatta, E.G.; Stern, M.D.; Silverman, H.S. Sodium channel blockade reduces hypoxic sodium loading and sodium-dependent calcium loading. Circulation 1994, 90, 391-399.
22. 2+ exchange. Circ. Res. 1992, 71, 547-557.
23. Schanne, F.A.; Kane, A.B.; Young, E.E.; Farber, J.L. Calcium dependence of toxic cell death: A final common pathway. Science 1979, 206, 700-702.
24. +-dependent glutamate transport. J. Neurosci. 1999, 19, RC16.
25. Lipton, S.A.; Rosenberg, P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 1994, 330, 613-622.
26. Doble, A. The pharmacology and mechanism of action of riluzole. Neurology 1996, 47 (Suppl. 4), S233-S241.
27. Park, E.; Velumian, A.A.; Fehlings, M.G. The role of excitotoxicity in secondary mechanisms of spinal cord injury: A review with an emphasis on the implications for white matter degeneration. J. Neurotrauma 2004, 21, 754-774.
28. Schnell, L.; Fearn, S.; Schwab, M.E.; Perry, V.H.; Anthony, D.C. Cytokine-induced acute inflammation in the brain and spinal cord. J. Neuropathol. Exp. Neurol. 1999, 58, 245-254.
29. Kobrine, A.I.; Evans, D.E.; LeGrys, D.C.; Yaffe, L.J.; Bradley, M.E. Effect of intravenous lidocaine on experimental spinal cord injury. J. Neurosurg. 1984, 60, 595-601.
30. Teng, Y.D.; Wrathall, J.R. Local blockade of sodium channels by tetrodotoxin ameliorates tissue loss and long-term functional deficits resulting from experimental spinal cord injury. J. Neurosci. 1997, 17, 4359-4366.
31. Schwartz, G.; Fehlings, M.G. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: Improved behavioral and neuroanatomical recovery with riluzole. J. Neurosurg. 2001, 94, 245-256.
32. Kwon, B.K.; Stammers, A.M.; Belanger, L.M.; Bernardo, A.; Chan, D.; Bishop, C.M.; Slobogean, G.P.; Zhang, H.; Umedaly, H.; Giffin, M.; et al. Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J. Neurotrauma 2010, 27, 669-682.
33. Wu, Y.; Satkunendrarajah, K.; Teng, Y.; Chow, D.S.; Buttigieg, J.; Fehlings, M.G. Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury. J. Neurotrauma 2013, 30, 441-452.
34. Wu, Y.; Satkunendrarajah, K.; Fehlings, M.G. Riluzole improves outcome following ischemia-reperfusion injury to the spinal cord by preventing delayed paraplegia. Neuroscience 2014, 265, 302-312.
35. Ates, O.; Cayli, S.R.; Gurses, I.; Turkoz, Y.; Tarim, O.; Cakir, C.O.; Kocak, A. Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. J. Clin. Neurosci. 2007, 14, 658-665.
36. Lang-Lazdunski, L.; Heurteaux, C.; Vaillant, N.; Widmann, C.; Lazdunski, M. Riluzole prevents ischemic spinal cord injury caused by aortic crossclamping. J. Thorac. Cardiovasc. Surg. 1999, 117, 881-889.
37. Lips, J.; de Haan, P.; Bodewits, P.; Vanicky, I.; Dzoljic, M.; Jacobs, M.J.; Kalkman, C.J. Neuroprotective effects of riluzole and ketamine during transient spinal cord ischemia in the rabbit. Anesthesiology 2000, 93, 1303-1311.
38. Mu, X.; Azbill, R.D.; Springer, J.E. Riluzole and methylprednisolone combined treatment improves functional recovery in traumatic spinal cord injury. J. Neurotrauma 2000, 17, 773-780.
39. Stutzmann, J.M.; Pratt, J.; Boraud, T.; Gross, C. The effect of riluzole on post-traumatic spinal cord injury in the rat. Neuroreport 1996, 7, 387-392.
40. Hama, A.; Sagen, J. Antinociceptive effect of riluzole in rats with neuropathic spinal cord injury pain. J. Neurotrauma 2011, 28, 127-134.
41. Kitzman, P.H. Effectiveness of riluzole in suppressing spasticity in the spinal cord injured rat. Neurosci. Lett. 2009, 455, 150-153.
42. Grossman, R.G.; Fehlings, M.G.; Frankowski, R.F.; Burau, K.D.; Chow, D.S.; Tator, C.; Teng, A.; Toups, E.G.; Harrop, J.S.; Aarabi, B.; et al. A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J. Neurotrauma 2014, 31, 239-255.
43. Grossman, R.G.; Toups, E.G.; Frankowski, R.F.; Burau, K.D.; Howley, S. North American Clinical Trials Network for the Treatment of Spinal Cord Injury: Goals and progress. J. Neurosurg. Spine 2012, 17, 6-10.
44. Maynard, F.M., Jr.; Bracken, M.B.; Creasey, G.; Ditunno, J.F., Jr.; Donovan, W.H.; Ducker, T.B.; Garber, S.L.; Marino, R.J.; Stover, S.L.; Tator, C.H.; et al. International Standards for Neurological and Functional Classification of Spinal Cord Injury. American Spinal Injury Association. Spinal Cord 1997, 35, 266-274.
45. Chow, D.S.; Teng, Y.; Toups, E.G.; Aarabi, B.; Harrop, J.S.; Shaffrey, C.I.; Johnson, M.M.; Boakye, M.; Frankowski, R.F.; Fehlings, M.G.; et al. Pharmacology of riluzole in acute spinal cord injury. J. Neurosurg. Spine 2012, 17, 129-140.
46. Grossman, R.G.; Frankowski, R.F.; Burau, K.D.; Toups, E.G.; Crommett, J.W.; Johnson, M.M.; Fehlings, M.G.; Tator, C.H.; Shaffrey, C.I.; Harkema, S.J.; et al. Incidence and severity of acute complications after spinal cord injury. J. Neurosurg. Spine 2012, 17, 119-128.
47. Mestre, H.; Alkon, T.; Salazar, S.; Ibarra, A. Spinal cord injury sequelae alter drug pharmacokinetics: An overview. Spinal Cord 2011, 49, 955-960.
48. Vertiz-Hernandez, A.; Castaneda-Hernandez, G.; Martinez-Cruz, A.; Cruz-Antonio, L.; Grijalva, I.; Guizar-Sahagun, G. L-arginine reverses alterations in drug disposition induced by spinal cord injury by increasing hepatic blood flow. J. Neurotrauma 2007, 24, 1855-1862.
49. Nagoshi, N.; Fehlings, M.G. Investigational drugs for the treatment of spinal cord injury: Review of preclinical studies and evaluation of clinical trials from Phase I to II. Expert Opin. Investig. Drugs 2015, 1-14.